



Certificate of Mailing (37 C.F.R. §1.10):

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop: Amendments, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 21st day of September 2006.

s/

Julie Agozino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
JOHN WILLIAM BENBOW

Serial No.: 10/580,615

Filed: May 23, 2006

For: **AMINOPYRAZOLE DERIVATIVES AS
GSK-3 INHIBITORS**

Group Art Unit: TBA

Examiner: TBA

Mail Stop: Amendments
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

- | | | |
|----|--|------------------|
| 1. | Transmittal of Information Disclosure Statement | 2 pages; |
| 2. | Information Disclosure Statement Form PTO/SB/08A | 9 pages; |
| 3. | References (142 cited) | 44 references; |
| 4. | Return Postcard | 1 postcard; and |
| 5. | Total Fee Due | Deposit Account. |

Respectfully submitted,

Date: Sep. 21, 2006


Ye Hua

Attorney For Applicants
Registration No. 53,042

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10555 Science Center Drive
San Diego, California 92121
Phone: (858) 622-3020
Fax: (858) 678-8233



Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop: Amendments, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 21st day of September 2006.

s/

Julie Aggino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
John William Benbow

Serial No.: 10/580,615

Confirmation No.: TBA

Filed: May 23, 2006

For: AMINOPYRAZOLE DERIVATIVES AS
GSK-3 INHIBITORS

Group Art Unit: TBA

Examiner: TBA

Mail Stop: Amendment
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97

37 CFR § 1.97(b)

- ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 CFR § 1.97(c)

- ☒ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.

- ☐ Applicant requests that the Examiner consider the following copending applications:

Application Serial No.	Filing Date


- ☐ Copies of these copending applications are enclosed.
- ☒ Applicant hereby requests consideration of the Information Disclosure Statement, PTO/SB/08, submitted herewith. Copies of the cited references, except as noted below, are enclosed.
- ☐ This application is a continuation, divisional or continuation-in-part of Serial No. [REDACTED]. Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.
- ☒ Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (waiver of 37 CFR 1.98(a)(2)(iii) pursuant to 37 CFR 1.183).
- ☐ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 500329. A duplicate copy of this form is enclosed.

Respectfully submitted,

Date:

Sep. 21, 2006


Ye Hua
Attorney For Applicant
Registration No. 53,042

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10555 Science Center Drive
San Diego, California 92121
Phone: (858) 622-3020
Fax: (858) 678-8233

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/580,615
Filing Date	May 23, 2006
First Named Inventor	John William Benbow
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC26084A

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ²			
	AA	6,387,931			Withdrawn
	AB	3,819,706	06-25-1974	Mehta, N.	
	AC	3,885,046	05-20-1975	Mehta, N.	
	AD	4,007,196	02-08-1977	Christensen, J., et al	
	AE	4,085,225	04-18-1978	Welle, J., et al	
	AF	4,314,081	02-02-1982	Molloy, B., et al.	
	AG	4,338,317	07-06-1982	Temple, Jr., D., et al	
	AH	4,423,049	12-27-1983	Temple, Jr., D.	
	AI	4,535,186	08-13-1985	Husbands, G., et al	
	AJ	4,536,518	08-20-1985	Welch, Jr., W., et al	
	AK	4,690,931	09-01-1987	Wick, A., et al	
	AL	4,804,663	02-14-1989	Kennis, L., et al	
	AM	4,833,142	05-23-1989	Hartog, J., et al	
	AN	4,895,841	01-23-1990	Sugimoto, H., et al	
	AO	4,948,807	08-14-1990	Rosin, M., et al	
	AP	5,122,525	06-16-1992	Bright, G., et al	
	AQ	5,162,339	11-10-1992	Lowe III, J.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/580,615
Filing Date	May 23, 2006
First Named Inventor	John William Benbow
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC26084A

	AR	5,185,343	02-09-1993	Chenard, B.	
	AS	5,229,382	07-20-1993	Chakrabarti, J., et al	
	AT	5,232,929	08-03-1993	Desai, M., et al	
	AU	5,240,958	08-31-1993	Campion, C., et al	
	AV	5,272,160	12-21-1993	Chenard, B.	
	AW	5,310,763	05-10-1994	Campion, C., et al	
	AX	5,312,925	05-17-1994	Allen, D., et al	
	AY	5,332,817	07-26-1994	Desai, M., et al	
	AZ	5,356,905	10-18-1994	Butler, T.	
	BA	5,358,948	10-25-1994	Bradshaw, K.	
	BB	5,373,018	12-13-1994	Cugola, A., et al	
	BC	5,455,258	10-03-1995	MacPherson, L., et al	
	BD	5,466,823	11-14-1995	Talley, J., et al	
	BE	5,474,995	12-12-1995	Ducharme, Y., et al	
	BF	5,506,242	04-09-1996	MacPherson, L., et al	
	BG	5,510,350	04-23-1996	Oxford, A., et al	
	BH	5,530,161	06-25-1996	Campion, C., et al	
	BI	5,538,984	07-23-1996	Villalobos, A., et al	
	BJ	5,552,419	09-03-1996	MacPherson, L., et al	
	BK	5,587,458	12-24-1996	King, C., et al	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/580,615
Filing Date	May 23, 2006
First Named Inventor	John William Benbow
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC26084A

	BL	5,602,169	02-11-1997	Hewawasam, P., et al	
	BM	5,633,272	05-27-1997	Talley, J., et al	
	BN	5,672,615	09-30-1997	MacPherson, L., et al	
	BO	5,679,683	10-21-1997	Bridges, A., et al	
	BP	5,703,240	12-30-1997	Armour, D., et al	
	BQ	5,716,965	02-10-1998	Ito, F., et al	
	BR	5,719,147	02-17-1998	Dorn, C., et al	
	BS	5,744,480	04-28-1998	Lowel II, J., et al	
	BT	5,744,483	04-28-1998	Butler, T., et al	
	BU	5,747,498	05-05-1998	Schnur, R., et al	
	BV	5,763,699	06-09-1998	German, L., et al	
	BW	5,773,450	06-30-1998	Lowe III, J., et al	
	BX	5,792,783	08-11-1998	Tang, P., et al	
	BY	5,807,867	09-15-1998	Ito, F., et al	
	BZ	5,834,504	11-10-1998	Tang, P., et al	
	CA	5,843,966	12-01-1998	Armour, D., et al	
	CB	5,851,999	12-22-1998	Ullrich, A., et al	
	CC	5,852,038	12-22-1998	Ito, F., et al	
	CD	5,861,510	01-19-1999	Piscopio, A., et al	
	CE	5,863,949	01-26-1999	Robinson, R., et al	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/580,615
Filing Date	May 23, 2006
First Named Inventor	John William Benbow
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC26084A

	CF	5,877,305	03-02-1999	Huston, J., et al	
	CG	5,883,113	03-16-1999	Tang, P., et al	
	CH	5,886,020	03-23-1999	Tang, P., et al	
	CI	5,886,009	03-23-1999	Ito, F., et al	
	CJ	5,932,595	08-03-1999	Bender, S., et al	
	CK	5,939,433	08-17-1999	Ito, F., et al	
	CL	5,962,472	10-05-1999	Bourson, A., et al	
	CM	5,994,351	11-30-1999	Robinson, R., et al	
	CN	6,046,213	04-04-2000	Chenard, B., et al	
	CO	6,051,593	04-18-2000	Tang, P., et al	
	CP	6,077,864	06-20-2000	Burgess, L., et al	
	CQ	6,087,392	07-11-2000	Reiter, L.	
	CR	6,090,852	07-18-2000	Dack, K., et al	
	CS	6,110,964	08-29-2000	Robinson, R.	
	CT	6,114,371	09-05-2000	Tang, P., et al	
	CU	6,124,317	09-26-2000	Bigge, C., et al	
	CV	6,124,323	09-26-2000	Bigge, C., et al	
	CW	6,130,234	10-10-2000	Bigge, C., et al	
	CX	6,133,305	10-17-2000	Tang, P., et al	
	CY	6,147,061	11-14-2000	Reiter, L.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/580,615
Filing Date	May 23, 2006
First Named Inventor	John William Benbow
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC26084A

	CZ	6,147,074	11-14-2000	Robinson, R., et al	
	DA	6,162,804	12-19-2000	Bilodeau, M., et al	
	DB	6,174,889	01-16-2001	Cockerill, G., et al	
	DC	6,207,669	03-27-2001	Cockerill, G., et al	
	DD	6,207,669	03-27-2001	Cockerill, G., et al	
	DE	6,218,404	04-17-2001	Bigge, C., et al	
	DF	6,235,741	05-22-2001	Bilodeau, M., et al	
	DG	6,291,455	09-18-2001	Thomas, A., et al	
	DH	6,294,532	09-25-2001	Thomas, A., et al	
	DI	6,303,636	10-16-2001	Robinson, R., et al	
	DK	6,310,238	10-30-2001	Sezi, R., et al	
	DL	6,333,036	12-25-2001	Arminjon, F., et al	
	DM	6,380,219	04-30-2002	Robinson, R., et al	
	DN	6,380,203	04-30-2002	Bilodeau, M., et al	
	DO	6,380,186	04-30-2002	Howard, H.	
	DP	6,391,874	05-21-2002	Cockerill, G., et al	
	DQ	6,395,734	05-28-2002	Tang, P., et al	
	DR	6,403,592	06-11-2002	Howard, H.	
	DS	6,423,708	07-23-2002	Gibbs, M., et al	
	DT	6,448,270	09-10-2002	Bigge, C., et al	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Complete if Known

Application Number	10/580,615
Filing Date	May 23, 2006
First Named Inventor	John William Benbow
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC26084A

	DU	6,462,048	10-08-2002	Howard, H.	
--	----	-----------	------------	------------	--

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	DV	WO 02/18346	03-07-2002	Pfizer Products Inc		
	DW	WO 98/34915	08-13-1998	Pfizer Inc		
	DX	WO 98/34918	08-13-1998	Pfizer Inc		
	DY	WO 98/14451	04-09-1998	Novartis AG		
	DZ	WO 99/24440	05-20-1999	Pfizer Products Inc		
	EA	WO 97/13760	04-17-1997	Glaxo Group Limited		
	EB	WO 99/35132	07-15-1999	Glaxo Group Limited		
	EC	WO 99/35146	07-15-1999	Glaxo Group Limited		
	ED	WO 94/21619	09-29-1994	Pfizer Inc		
	EE	WO 97/23202	07-03-1997	State of Oregon		
	EF	WO 98/18793	05-07-1998	Merck Patent GMBH	No English Equiv.	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EG	ALI, A., et al., "Glycogen Synthase Kinase-3: Properties, Functions, And Regulation," <i>Chem. Rev.</i> , 2001, 2527-2540, vol. 101.	
	EH	BAAR, K., et al., "Phosphorylation Of p70 ^{S6k} Correlates With Increased Skeletal Muscle Mass Following Resistance Exercise," <i>Am. J. Physiol.</i> , 1999, C120-C127, vol. 276.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/580,615
Filing Date	May 23, 2006
First Named Inventor	John William Benbow
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC26084A

EL	BADORFF, C., et al., "Fas Receptor Signaling Inhibits Glycogen Synthase Kinase 3 β And Induces Cardiac Hypertrophy Following Pressure Overload," <i>The Journal Of Clinical Investigation</i> , 2002, 373-381, vol. 109, no. 3.
EJ	BARNES, P., "Cytokine Modulators As Novel Therapies For Asthma," <i>Ann. Rev. Pharmacol. Toxicol.</i> , 2002, 81-98, vol. 42.
EK	BEALS, C., et al., "Nuclear Export Of NF-ATc Enhanced By Glycogen Synthase Kinase-3," <i>Science</i> , 1997, 1930-1933, vol. 275.
EL	BERGE, S., et al., "Pharmaceutical Salts," <i>Journal of Pharmaceutical Science</i> , 1977, 1-19, vol. 66, no. 1.
EM	BRUNN, G., et al., "Phosphorylation Of The Translational Repressor PHAS-I By The Mamalian Target Of Rapamycin," <i>Science</i> , 1997, 99-101, vol. 277.
EN	CASTRO A., et al., "Inhibition Of Tau Phosphorylation: A New Therapeutic Strategy For The Treatment Of Alzheimer's Disease And Other Neurodegenerative Disorders," <i>Expert Opinion On Therapeutic Patents</i> , 2000, 1519-1527, vol. 10, no. 10.
EO	COHEN, P., "The Role Of Protein Phosphorylation In Human Health And Disease Delivered On June 30 th 2001 At the FEBS Meeting In Lisbon," <i>Eur. J. Biochem.</i> , 2001, 5001-5010, vol. 268.
EP	CROSS, D., et al., "Selective Small-Molecule Inhibitors Of Glycogen Synthase Kinase-3 Activity Protect Primary Neurones From Death," <i>Journal Of Neurochemistry</i> , 2001, 94-102, vol. 77.
EQ	EASTMAN, Q., et al., "Regulation Of LEF-1/TCF Transcription Factors By Wnt And Other Signals," <i>Current Opinion In Cell Biology</i> , 1999, 233-240, vol. 11.
ER	ELDAR-FINKELMAN, H., "Glycogen Synthase Kinase 3: an Emerging Therapeutic Target," <i>Trends In Molecular Medicine</i> , 2002, 126-132, vol. 8, no. 3.
ES	EMBI, N., et al., "Glycogen Synthase Kinase-3 From Rabbit Skeletal Muscle," <i>Euro. J. Biochem</i> , 1980, 519-527, vol. 107.
ET	FUCHS, E., et al., "At The Roots Of A Never-Ending Cycle," <i>Developmental Cell</i> , 2001, 13-25, vol. 1.
EU	GRIMES, C., et al., "The Multifaceted Roles Of Glycogen Synthase Kinase 3 β In Cellular Signaling," <i>Progress In Neurobiology</i> , 2001, 391-426, vol. 65.
EV	HAQ, S., et al., "Glycogen Synthase Kinase-3 β Is A Negative Reulator Of Cardiomyocyte Hypertrophy," <i>The Journal Of Cell Biology</i> , 2000, 117-129, vol. 151, no. 1.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/580,615
Filing Date	May 23, 2006
First Named Inventor	John William Benbow
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC26084A

EW	KIM, L., et al., "GSK3, A Master Switch Regulating Cell-Fate Specification And Tumorigenesis," <i>Current Opinion In Genetics & Development</i> , 2000, 508-514, vol. 10.
EX	KLEIN, P., et al., "A Molecular Mechanism For The Effect Of Lithium On-Development," <i>Proc. Natl. Acad. Sci. USA</i> , 1996, 8455-8459, vol. 93.
EY	LAU, K., et al., "Expression Analysis Of Glycogen Synthase Kinase-3 In Human Tissues," <i>J. Peptide Res.</i> , 1999, 85-91, vol. 54.
EZ	MEIJER, L., et al., "Properties And Potential Applications Of Chemical Inhibitors Of Cyclin-Dependent Kinases," <i>Pharmacol. And Ther.</i> , 1999, 279-284, vol. 82, nos. 2-3.
FA	MILLAR, S., et al., "WNT Signaling In The Control Of Hair Growth And Structure," <i>Developmental Biology</i> , 1999, 133-149, vol. 207.
FB	NIKOULINA, S., et al., "Inhibition Of Glycogen Synthase Kinase 3 Improves Insulin Action And Glucose Metabolism In Human Skeletal Muscle," <i>Diabetes</i> , 2002, 2190-2198, vol. 51.
FC	ORENA, S., et al., "Inhibition Of Glycogen-Synthase Kinase 3 Stimulates Glycogen Synthase And Glucose Transport By Distinct Mechanisms In 3T3-L1 Adipocytes," <i>The Journal of Biological Chemistry</i> , 2000, 15765-15772, vol. 275, no. 21.
FD	REGAN, J., et al., "Pyrazole Urea-Based Inhibitors Of p38 MAP Kinase: From Lead Compound To Clinical Candidate," <i>J. Med. Chem.</i> , 2002, 2994-3008, vol. 45.
FE	RHOADS, R., et al., "Signal Transduction Pathways That Regulate Eukaryotic Protein Synthesis," <i>The Journal Of Biological Chemistry</i> , 1999, 30337-30340, vol. 274, no. 43.
FF	SASAKI, C., et al., "Different Expression Of Glycogen Synthase Kinase-3 β Between Young And Old Rat Brains After Transient Middle Cerebral Artery Occlusion," <i>Neurological Research</i> , 2001, 588-592, vol. 23.
FG	SAUSVILLE, E., et al., "Cyclin-Dependent Kinases: Initial Approaches To Exploit a Novel Therapeutic Target," <i>Pharmacol. And Ther.</i> , 1999, 285-292, vol. 82, nos. 2-3.
FH	SUMMERS, S., et al., "The Role of Glycogen Synthase Kinase 3 β In Insulin-Stimulated Glucose Metabolism," <i>The Journal of Biological Chemistry</i> , 1999, 17934-17940, vol. 274, no. 25.
FI	TONG, H., "Phosphorylation Of Glycogen Synthase Kinase-3 β During Preconditioning Through A Phosphatidylinositol-3-Kinase-Dependent Pathway Is Cardioprotective," et al., <i>Circulation Research</i> , 2002, 377-379, vol. 90.
FJ	VIJAYARAGHAVAN, S., et al., "Sperm Motility Development In The Epididymis Is Associated With Decreased Glycogen Synthase Kinase-3 And Protein Phosphatase 1 Activity," <i>Biology Of Reproduction</i> , 1996, 709-718, vol. 54.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	10/580,615
Filing Date	May 23, 2006
First Named Inventor	John William Benbow
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC26084A

	FK	VYAS, D., et al., "GSK-3 β Negatively Regulates Skeletal Myotube Hypertrophy," <i>Am. J. Physiol. Cell Physiol.</i> , 2002, C545-C551, vol. 283	
	FL	WILLIAMS, R., et al., "Lithium Therapy And Signal Transduction," <i>TIPS</i> , 2000, 61-64, vol. 21.	
	FM	WOODGETT, J., "Molecular Cloning And Expression Of Glycogen Synthase Kinase-3/Factor A," <i>The EMBO Journal</i> , 1990, 2431-2438, vol. 9, no. 8.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.